Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Intangibles (2023 - 2026)

bioAffinity Technologies has reported Intangibles over the past 4 years, most recently at $702222.0 for Q1 2026.

  • Quarterly Intangibles fell 7.67% to $702222.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $702222.0 through Mar 2026, down 7.67% year-over-year, with the annual reading at $716806.0 for FY2025, 7.53% down from the prior year.
  • Intangibles was $702222.0 for Q1 2026 at bioAffinity Technologies, down from $716806.0 in the prior quarter.
  • Over five years, Intangibles peaked at $2.2 million in Q1 2024 and troughed at $702222.0 in Q1 2026.
  • The 4-year median for Intangibles is $775139.0 (2024), against an average of $1.0 million.
  • Year-over-year, Intangibles dropped 7.0% in 2024 and then tumbled 65.79% in 2025.
  • A 4-year view of Intangibles shows it stood at $833472.0 in 2023, then dropped by 7.0% to $775139.0 in 2024, then dropped by 7.53% to $716806.0 in 2025, then dropped by 2.03% to $702222.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Intangibles are $702222.0 (Q1 2026), $716806.0 (Q4 2025), and $731389.0 (Q3 2025).